CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 32 enrolled
Drug / intervention
hydroxychloroquine +1 moredrug
Likely dose
hydroxychloroquine 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01326533
NCT01326533Phase 4Completed
CompareCT.gov

Mechanisms of Action of Hydroxychloroquine in Reducing Risk of Type 2 Diabetes

University of Pittsburgh·interventional·Posted Mar 31, 2011·Updated Feb 26, 2016

In Brief

A Phase 4 clinical trial evaluating hydroxychloroquine and Placebo for Pre-diabetes. Completed, enrolled 32 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the short-term effects of the antimalarial medication, hydroxychloroquine (HCQ), compared with placebo using frequently sampled intravenous glucose tolerance testing (FSIGTT) methodology to study changes in insulin secretion and glucose tolerance in subjects at risk for developing Type 2 diabetes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPre-diabetes
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 31, 2011
Enrollment StartMar 1, 2011
Primary CompletionMar 1, 2013
Study CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 15.3 years ago

Interventions

hydroxychloroquinedrug

Thirteen weeks of oral hydroxychloroquine (400 mg/day) provided as capsules

Placeboother

Thirteen weeks of oral placebo provided as capsules